1
|
Nowak J, Pyka L, Kurdziel M, Siedlecki L, Niedziela J, Krajewski A, Skowron W, Danicic M, Kazik A, Gasior M. P4510Impact of secondary tricuspid regurgitation on survival in heart failure - insights from COMMIT-HF registry. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Functional tricuspid regurgitation (fTR) is common in left sided heart disease, especially in patients with concomitant left-sided valvular diseases and can lead to functional impairment and reduced survival. However, the impact of fTR on survival in chronic heart failure with reduced left ventricular ejection fraction (HFrEF) without severe left valvular diseases (LVD) is not fully established. The aim of the present study was to observe if moderate to severe fTR may influence the survival in patients with HFrEF without severe LVD.
Methods
We have analyzed a large single-center registry (n=2731) of HFrEF patients treated in a large-volume cardiovascular center between 2009–2015. After exclusion of patients with severe aortic and mitral valve disease we have included 2435 patients with HFrEF (left ventricular ejection fraction (LVEF) ≤35%). Functional moderate to severe tricuspid regurgitation without severe left valvular diseases was present in 465 patients. Twelve -month vital status was available for the whole patient population. Univariate and multivariate Cox proportional hazard regression models were performed to evaluate the relationship between moderate to severe fTR and mortality in the study group.
Results
Comparison of clinical data of fTR and non-fTR in HFrEF patients revealed some significant differences (age 63.3±12.9 vs 61.3±12.4, p=0.002; female sex 25.8% vs 17,9%, p<0.001; chronic kidney disease stage III-V 45.3 vs 26.6%, p=0.001; atrial fibrillation 52.4% vs 28.5%, p<0.001). Twelve-month all-cause mortality was over 2-fold higher in the fTR group (21.2% vs 8.1%, p<0.001). There were no significant differences with regard to the medical treatment, implantable defibrillator or cardiac resynchronization therapy. The presence of fTR was identified as an independent echocardiographic factor impaired 12-month all-cause survival (HR 1.59, CI 1.2- 2.09, p<0.001, figure 1)
Conclusion
Apart from the LVEF, the presence of moderate to severe fTR may predict 12-month all-cause mortality in patients with HFrEF.
Acknowledgement/Funding
None
Collapse
Affiliation(s)
- J Nowak
- Silesian Center for Heart Diseases (SCHD), 3rd Department of Cardiology, Zabrze, Poland
| | - L Pyka
- Silesian Center for Heart Diseases (SCHD), 3rd Department of Cardiology, Zabrze, Poland
| | - M Kurdziel
- Silesian Center for Heart Diseases (SCHD), 3rd Department of Cardiology, Zabrze, Poland
| | - L Siedlecki
- Silesian Center for Heart Diseases (SCHD), 3rd Department of Cardiology, Zabrze, Poland
| | - J Niedziela
- Silesian Center for Heart Diseases (SCHD), 3rd Department of Cardiology, Zabrze, Poland
| | - A Krajewski
- Silesian Center for Heart Diseases (SCHD), 3rd Department of Cardiology, Zabrze, Poland
| | - W Skowron
- Silesian Center for Heart Diseases (SCHD), 3rd Department of Cardiology, Zabrze, Poland
| | - M Danicic
- Silesian Center for Heart Diseases (SCHD), 3rd Department of Cardiology, Zabrze, Poland
| | - A Kazik
- Silesian Center for Heart Diseases (SCHD), 3rd Department of Cardiology, Zabrze, Poland
| | - M Gasior
- Silesian Center for Heart Diseases (SCHD), 3rd Department of Cardiology, Zabrze, Poland
| |
Collapse
|
2
|
Pyka L, Hawranek M, Tajstra M, Siedlecki L, Gorol J, Gadula-Gacek E, Pres D, Lekston A, Gasior M. P956Management of coronary artery disease in elderly patients with ischemic heart failure and reduced ejection fraction - insights from the COMMIT-HF study. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz747.0550] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Heart failure (HF) is one of the most important global health problems in developed and ageing societies. Coronary artery disease (CAD) is the most common etiologic factor, related to poor outcomes. Data on CAD management in HF is scarce, especially when addressing subpopulations often omitted in randomized trials, such as the elderly.
Purpose
With a large cohort of HF patients (n=2730) we have decided to assess the clinical profile, treatment modalities and outcomes in elderly patients undergoing percutaneous coronary intervention (PCI).
Methods
We analyzed a large single-center all-comer registry of HF patients (left ventricular ejection fraction LVEF≤35%) treated in a large-volume cardiovascular center (2009–2015). Acute coronary syndromes on admission were excluded. Patients with ischemic etiology were selected for further analysis (n=1703) and subsequently divided into the elderly (≥75 y.o., n=346) and young (<75 y.o., n=1357) subgroups.
Results
The elderly group had understandably a worse clinical profile (mean age 79,1±3,5 vs 61,2±8,2, p<0,001; male 75,2 vs 85,4%, p<0,001; NYHA III & IV 60,3 vs 49,6%, p=0,07; diabetes 50,3 vs 44,9%, p=0,07; AF 35,8 vs 22,0%; p≤0,001; anemia 52,6 vs 36,7%, p<0,001; chronic kidney disease stage III-V 54,1 vs 28,9%, p<0,001; severe mitral insufficiency 13,3 vs 8,7%, p=0,01; history of myocardial infarction 68,8 vs 67,4%, p=0,62).ICD or CRT-D were implanted less frequently in the elderly (56,1 vs 68,5%; p<0,001). Echo analysis revealed significantly better LVEF (27,95,3± vs 25,9±6,0%, p<0,001) and less ventricular dilation (LVEDV 159±61 vs 205±82 ml, p<0,001).
Coronary angiography was performed frequently in both groups (78,6 vs 74,9%, p=0,15). Significant lesions were observed in 73,5 and 65,0% of cases respectively (p=0,008). The elderly were insignificantly less frequently qualified for CABG (9,0 vs 12,5%, p=0,17). Proportion of patients qualified for medical management of CAD was similar (23,5 vs 20,7%, p=0,40). PCI was performed frequently in both groups (59,5 vs 57,9%, p=0,69), often as multi-vessel procedures (34,4 vs 32,4%, p=0,67). There was a trend towards more complete revascularization in the younger patients (50,0 vs 59,5%, p=0,06). 12-month all-cause mortality was significantly higher in the elderly (20,3 vs 7,8%, p<0,001). Periprocedural compilications were very low and comparable (bleeding and/or need for transfusion, stroke and myocardial infarction). PCI itself was not a factor influencing long term outcomes (HR 0,75, 95% CI 0,51–1,1, p=0,15). Cox regression analysis revealed that prior stroke, ejection fraction, ICD and beta-blockers were the factors influencing survival (figure 1).
Conclusions
The analysis shows that PCI is a viable treatment option in the elderly population and when indicated can be performed safely, with good short and long term results. Interventions such as ICD implantation or optimal medical therapy of HF should always be considered.
Acknowledgement/Funding
None
Collapse
Affiliation(s)
- L Pyka
- Silesian Center for Heart Diseases (SCHD), 3rd Department of Cardiology, Zabrze, Poland
| | - M Hawranek
- Silesian Center for Heart Diseases (SCHD), 3rd Department of Cardiology, Zabrze, Poland
| | - M Tajstra
- Silesian Center for Heart Diseases (SCHD), 3rd Department of Cardiology, Zabrze, Poland
| | - L Siedlecki
- Silesian Center for Heart Diseases (SCHD), 3rd Department of Cardiology, Zabrze, Poland
| | - J Gorol
- Silesian Center for Heart Diseases (SCHD), 3rd Department of Cardiology, Zabrze, Poland
| | - E Gadula-Gacek
- Silesian Center for Heart Diseases (SCHD), 3rd Department of Cardiology, Zabrze, Poland
| | - D Pres
- Silesian Center for Heart Diseases (SCHD), 3rd Department of Cardiology, Zabrze, Poland
| | - A Lekston
- Silesian Center for Heart Diseases (SCHD), 3rd Department of Cardiology, Zabrze, Poland
| | - M Gasior
- Silesian Center for Heart Diseases (SCHD), 3rd Department of Cardiology, Zabrze, Poland
| |
Collapse
|